Myo‐inositol modulates insulin and luteinizing hormone secretion in normal weight patients with polycystic ovary syndrome. Issue 5 (9th March 2014)

• Record Type: Journal Article
• Authors: Genazzani, Alessandro D.; Santagni, Susanna; Ricchieri, Federica; Campedelli, Annalisa; Rattighieri, Erika; Chierchia, Elisa; Marini, Giulia; Despini, Giulia; Prati, Alessia; Simoncini, Tommaso
• Is Part Of: Journal of obstetrics and gynaecology research. Volume 40:Issue 5(2014:May)
• Page Start: 1353
• Page End: 1360
• Publication Date: 2014-03-09
• Subjects: Gynecology -- Periodicals; Obstetrics -- Periodicals; 618.1005
• DOI: 10.1111/jog.12319
• Languages: English
• ISSNs: 1341-8076

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="jog12319-sec-0001" sec-type="section"> <title>Aim</title> <p>To investigate hormonal dynamics in a group of non‐obese polycystic ovary syndrome (PCOS) patients under myo‐inositol (MYO) administration.</p> </sec> <sec id="jog12319-sec-0002" sec-type="section"> <title>Methods</title> <p>Hormonal profiles, insulin response to oral glucose tolerance test (OGTT) and luteinizing hormone (LH) response to gonadotropin‐releasing hormone (GnRH) stimulation test before and after the administration of a preparation of MYO (3 g p.o. daily) mixed with lactoferrin and bromelin, in a group (<italic>n</italic> = 24) of normal weight PCOS patients.</p> </sec> <sec id="jog12319-sec-0003" sec-type="section"> <title>Results</title> <p>After the treatment interval, body mass index (BMI) did not change while LH, LH/follicle‐stimulating hormone, 17‐hydroxy‐progesterone and androstenedione decreased significantly. Insulin response to OGTT was significantly reduced after the treatment interval (<italic>P</italic> < 0.05) as well as GnRH‐induced LH response (<italic>P</italic> < 0.05). High‐sensitivity C‐reactive protein decreased significantly after the treatment interval.</p> </sec> <sec id="jog12319-sec-0004" sec-type="section"> <title>Conclusion</title> <p>MYO administration positively modulates insulin sensitivity in non‐obese PCOS patients without compensatory hyperinsulinemia, improving hormonal parameters. The presence of bromelin in the formulation modulated the pro‐inflammatory state that characterizes PCOS, independently of BMI.</p> </sec> </abstract>